NCT06835595Recruiting
TMS-related Measures as Biomarker of Cognitive Impairment in PD
Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline. The main questions it aims to answer are: * TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)? * TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 14 Feb 2025
- Start date
- 10 Sept 2025
- Primary completion date
- 1 Jan 2029
- Lead sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
- Diseases
- Parkinson disease
- NCT number
- NCT06835595
What you commit to
- Study type: Interventional
- Planned participants: 52
- From 10 Sept 2025 to the primary completion date, 1 Jan 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of a cochlear implant, ferromagnetic brain device or near the site of brain stimulation, pacemaker, brain electrodes for DBS, electromechanical devices with IPG, or any other implantable stimulator, including peripheral ones
- Treatment with anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics, or antidepressants in the last month
- Treatment with drugs that lower the seizure threshold (e.g., imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA, ecstasy, phencyclidine, ketamine, gamma-hydroxybutyrate, alcohol, theophylline)
- Active cochlear pathology (especially if currently receiving ototoxic drugs, such as aminoglycoside antibiotics)
Other illness
- Systemic diseases of significant severity, including cardiovascular and cerebrovascular conditions (e.g., active neoplasms requiring chemotherapy, or end-stage heart failure)
- Presence of any active neurological disease, in addition to PD
- History of epilepsy
- History of cerebrovascular, tumor-related, infectious, or metabolic brain conditions predisposing to seizures or causing symptomatic epilepsy
- Dementia according to the latest revision of the MDS criteria for PDD
Other
- Pregnancy or breastfeeding
- Alcoholism
Who the study is looking for
- Age \> 18 years
- Ability to undergo an extensive neuropsychological evaluation
- Ability to sign informed consent for the study
- Diagnosed with idiopathic PD according to the latest revision of the MDS criteria
- On stable and optimal antiparkinsonian therapy for at least four weeks
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto Adige Coordinator of this site? Confirm its status | Sterzing | Italy | Not yet recruiting |
| UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS) Coordinator of this site? Confirm its status | Trento | Italy | Recruiting |
| SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) Coordinator of this site? Confirm its status | Trieste | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.